title: Concurrent chemoradiotherapy with cisplatin and S-1 or vinorelbine for patients with stage III unresectable non-small cell lung cancer: A retrospective study.
abstract: BACKGROUND
  Concurrent chemoradiotherapy (CCRT) is the preferred treatment for stage III unresectable non-small cell lung cancer (NSCLC). However, there have been few reports on combination chemotherapy with radiation for second- and third-generation antitumor drugs, although clinical guidelines have recommended the use of these drugs along with platinum agents.
  
  
  METHODS
  We retrospectively analyzed the efficacy and toxicity of cisplatin and either S-1 or vinorelbine for treating stage III unresectable NSCLC patients who were treated with CCRT.
  
  
  RESULTS
  Between September 2006 and May 2014, 56 patients with unresectable stage III NSCLC were treated with CCRT with S-1 and cisplatin (median age: 63 years) and 58 patients were treated with CCRT with vinorelbine and cisplatin (median age: 61 years). The median follow-up time was 14.6 months in the S-1 arm and 28.0 months in the vinorelbine arm. We found no significant difference in progression-free survival (15.8 months vs. 10.1 months; p=0.15) and overall survival (33.7 months vs. 31.1 months; p=0.63) between the S-1 and vinorelbine arms, respectively. Severe (more than grade 3) leukopenia (35.7% vs. 98.2%; p<0.01), neutropenia (44.6% vs. 98.2%; p<0.01), and febrile neutropenia (1.8% vs. 46.6%, p<0.01) were significantly less frequent in the S-1 arm than in the vinorelbine arm. Treatment-related deaths were not observed in either arm.
  
  
  CONCLUSIONS
  CCRT with both S-1 or vinorelbine with cisplatin appears feasible based on their efficacy and toxicity profiles. Both treatments may be recommended as treatment options for patients with stage III unresectable NSCLC.
authors: Department of Medical Oncology, Hyogo Cancer Center, Akashi-City, Hyogo 673-8558, Japan. Electronic address: ntakase@hp.pref.hyogo.jp.
authors: Naoto
authors: N
authors: Takase
authors: Department of Thoracic Oncology, Hyogo Cancer Center, 13-70 Kitaoji-cho, Akashi-City, Hyogo 673-8558, Japan. Electronic address: hattori@hp.pref.hyogo.jp.
authors: Yoshihiro
authors: Y
authors: Hattori
authors: Department of Thoracic Oncology, Hyogo Cancer Center, 13-70 Kitaoji-cho, Akashi-City, Hyogo 673-8558, Japan. Electronic address: tatsu.kiriu@gmail.com.
authors: Tatsunori
authors: T
authors: Kiriu
authors: Department of Thoracic Oncology, Hyogo Cancer Center, 13-70 Kitaoji-cho, Akashi-City, Hyogo 673-8558, Japan. Electronic address: sho1.itoh@hp.pref.hyogo.jp.
authors: Shouichi
authors: S
authors: Itoh
authors: Department of Thoracic Oncology, Hyogo Cancer Center, 13-70 Kitaoji-cho, Akashi-City, Hyogo 673-8558, Japan. Electronic address: ykawa@hp.pref.hyogo.jp.
authors: Yoshitaka
authors: Y
authors: Kawa
authors: Department of Thoracic Oncology, Hyogo Cancer Center, 13-70 Kitaoji-cho, Akashi-City, Hyogo 673-8558, Japan. Electronic address: Masatsugu.Yamamoto@hp.pref.hyogo.jp.
authors: Masatsugu
authors: M
authors: Yamamoto
authors: Department of Thoracic Oncology, Hyogo Cancer Center, 13-70 Kitaoji-cho, Akashi-City, Hyogo 673-8558, Japan. Electronic address: urata@hp.pref.hyogo.jp.
authors: Yoshiko
authors: Y
authors: Urata
authors: Department of Thoracic Oncology, Hyogo Cancer Center, 13-70 Kitaoji-cho, Akashi-City, Hyogo 673-8558, Japan. Electronic address: tsmd@hp.pref.hyogo.jp.
authors: Temiko
authors: T
authors: Shimada
authors: Department of Therapeutic Radiology, Hyogo Cancer Center, Akashi-City, Hyogo 673-8558, Japan. Electronic address: tsuk@mub.biglobe.ne.jp.
authors: Kayoko
authors: K
authors: Tsujino
authors: Department of Therapeutic Radiology, Hyogo Cancer Center, Akashi-City, Hyogo 673-8558, Japan. Electronic address: soe@hp.pref.hyogo.jp.
authors: Toshinori
authors: T
authors: Soejima
authors: Department of Medical Oncology, Hyogo Cancer Center, Akashi-City, Hyogo 673-8558, Japan. Electronic address: negoro@hp.pref.hyogo.jp.
authors: Shunichi
authors: S
authors: Negoro
authors: Department of Thoracic Oncology, Hyogo Cancer Center, 13-70 Kitaoji-cho, Akashi-City, Hyogo 673-8558, Japan. Electronic address: satouchi@hp.pref.hyogo.jp.
authors: Miyako
authors: M
authors: Satouchi
mesh_terms: D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D002289:Carcinoma, Non-Small-Cell Lung / Q000628:therapy*; D059248:Chemoradiotherapy / Q000009:adverse effects / Q000379:methods*; D002945:Cisplatin / Q000008:administration & dosage*; D004338:Drug Combinations; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D010094:Oxonic Acid / Q000008:administration & dosage*; D012189:Retrospective Studies; D005641:Tegafur / Q000008:administration & dosage*; D014747:Vinblastine / Q000008:administration & dosage / Q000031:analogs & derivatives*; D000077235:Vinorelbine
chemical_list: D000970:Antineoplastic Agents; D004338:Drug Combinations; C079198:S 1 (combination); D005641:Tegafur; D014747:Vinblastine; D010094:Oxonic Acid; D002945:Cisplatin; D000077235:Vinorelbine
keywords: Chemoradiotherapy; Cisplatin; S-1; Unresectable lung cancer; Vinorelbine